FYI | INSM Message Board Posts

Insmed Incorporated

  INSM website

INSM   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  46258 of 49633  at  6/13/2019 7:17:20 PM  by

slimhere


FYI

Savara Down 75% After Study Doesn't Meet Primary Endpoint >SVRA

10:44 am ET June 13, 2019 (Dow Jones) Print

By Michael Dabaie

Savara Inc. (SVRA) shares fell 75% to $2.61 Thursday morning.

The orphan lung disease company said Wednesday the IMPALA Phase 3 study of Molgradex to treat autoimmune alveolar pulmonary proteinosis didn't meet its primary endpoint of alveolar-arterial oxygen gradient.

The study showed statistically significant improvement in the St. George's Respiratory Questionnaire, a key secondary endpoint, the company said.

The company said it plans to meet with the U.S. Food and Drug Administration and European Medicines Agency in the coming months to discuss the data and path forward.

JMP Securities cut Savara to Market Perform from Outperform.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 13, 2019 10:44 ET (14:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 231
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...